What Iasis Pharma does

Iasis Pharma (legal entity IASIS PHARMACEUTICALS HELLAS S.A.) is a privately held Greek pharmaceutical manufacturer headquartered in Athens, with production operations in Koropi (45,000 m² GMP-certified complex) and Kamatero. Founded in 1985, the company researches, develops, produces, and markets branded generic and proprietary pharmaceutical products across cardiovascular, central nervous system, dermatology, diabetes, gastroenterology, musculoskeletal, respiratory, anti-microbial, and vitamin therapeutic categories, serving Greek pharmacies and hospitals via its dedicated distribution partner Pharma Q and reaching international markets through an International Network division.

The company's product portfolio combines conventional branded generics with differentiated proprietary offerings, including original fixed-dose combinations (Rami-Amlo, Rami-Amlo plus, RosuZet) and unique dosage strengths such as Isotroin 30mg. Its most strategically distinct asset is the Chios Mastic (Pistacia lentiscus var. Chia) product line, developed around a Protected Designation of Origin ingredient and granted EMA Herbal Medicinal Product status in 2015 for functional dyspepsia and skin wound healing. Manufacturing leverages IMA (Italian) effervescent tablet technology, liquid and solid dosage lines, and a GMP-certified research center, supported by R&D partnerships with Harokopio University, the National and Kapodistrian University of Athens, and the Union of Chios Mastic Producers via the HYPER-MASTIC green-extraction research consortium.

Go-to-market relies on enterprise field sales to healthcare professionals, systematic exhibition presence at Panhellenic and international (CPhI) medical congresses, and medical science liaison engagement with specialty societies. Revenue is generated through one-time product sales via pharmacy, hospital, and export channels under Greece's regulated pharmaceutical pricing framework, with no public disclosure of pricing or unit economics. The company's strategic emphasis is on leveraging its EMA-approved herbal platform, proprietary fixed-dose combinations, and manufacturing scale to extend from the Greek domestic base into selected international markets.

Name

Iasis Pharma

Legal name

IASIS PHARMACEUTICALS HELLAS S.A.

Website

https://iasispharma.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Short description

Iasis Pharma is a Greek pharmaceutical manufacturer that develops, produces, and markets branded generics and proprietary medicines across multiple therapeutic areas, serving Greek pharmacies and hospitals via distribution partner Pharma Q and exporting internationally through CPhI-sourced partnerships.

Ownership category

akta.pro rank

Product category

Branded Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Branded generic pharmaceuticals
• Herbal medicine products
• Cardiovascular drug formulations
• Dermatology pharmaceuticals
• Fixed-dose combinations

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Branded Generic Pharmaceuticals: Sale of branded generic pharmaceutical products across multiple therapeutic categories (cardiovascular, CNS, dermatology, diabetes, gastrointestinal, musculoskeletal, respiratory, vitamins, anti-microbials) primarily in the Greek domestic market through pharmacies and hospitals. Products include original combinations and proprietary formulations.
2. Proprietary Herbal Medicines: Sale of proprietary herbal medicine products based on Chios Mastic (Mastiha var. Chia), including EMA-approved capsules for functional dyspepsia, powder formulation, and topical gel for skin conditions. Sold in Greece and international markets.
3. Original Proprietary Products: Sale of original fixed-dose combination products (Rami-Amlo, Rami-Amlo plus, RosuZet) and unique dosage strength products (Isotroin 30mg) that are not generic equivalents, commanding premium positioning in the market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Iasis Pharma researches, develops, manufactures, imports, and markets branded generic and proprietary pharmaceutical products across multiple therapeutic areas, including cardiovascular, dermatology, diabetes, gastroenterology, CNS, musculoskeletal, and respiratory. Its portfolio includes original fixed-dose combinations (RosuZet, Rami-Amlo, Rami-Amlo plus), unique dosage strengths (Isotroin 30mg), and EMA-approved Chios Mastic herbal medicine products (capsules, powder, and cutaneous gel). Manufacturing is performed in GMP-certified facilities in Greece.

Product overview

Iasis Pharma is a Greek pharmaceutical company (IASIS PHARMACEUTICALS HELLAS S.A.) that manufactures high-quality generic and proprietary pharmaceutical products. The company operates in the pharmaceutical and cosmetics industry with a diverse portfolio covering multiple therapeutic areas including cardiovascular system (RosuZet®, Rami-Amlo®, Rami-Amlo plus®, Licepler®, COVED®), diabetes (Glucofree®, Glucoplus®), dermatology (Isotroin®, Modiwart®, Combi®, Sensibio®, Flusterix®), gastroenterology (Mastiha var. Chia products including caps, powder, and gel formulations), musculoskeletal/anti-inflammatory (ETROZAC®), and nutritional supplements (MAG-IASIS®). The company also produces a wide range of generic medications across therapeutic categories including antibiotics, vitamins, and central nervous system treatments. Iasis Pharma maintains international operations and has received EMA approval for its flagship herbal product, Mastiha var. Chia.

Differentiator

Problem solved

Functional benefit

Brands

• Mastiha var. Chia Products: Product line featuring Chios mastic (Pistacia lentiscus var. Chia) including capsules, powder, and cutaneous gel for gastrointestinal and dermatological applications
• PHARMA Q

Products and services

• Isotroin® Isotretinoin soft gel capsules for severe acne treatment resistant to systemic antibiotics and topical therapy, available in 10mg, 20mg, 30mg (unique), and 40mg strengths.
• RosuZet® Original fixed-dose combination of Rosuvastatin and Ezetimibe in film-coated tablets for lipid modification, available in 5/10mg, 10/10mg, 20/10mg, and 40/10mg strengths.
• Rami-Amlo® Original fixed-dose combination of Ramipril and Amlodipine in hard capsules for hypertension treatment, available in 28 capsules with 4 strengths.
• Rami-Amlo plus® Original fixed-dose combination of Ramipril, Amlodipine, and Hydrochlorothiazide for hypertension treatment, available in 30 capsules with wide dosage range.
• Mastiha var. Chia caps® Unique herbal medicine containing natural Chios mastic Pistacia lentiscus resin (350mg/capsule) for functional dyspepsia, EMA approved since 2015.
• Mastiha var. Chia Cutaneous Regenerative Gel Regenerative and soothing gel (30ml) for minor skin inflammations and healing of microtraumas, containing 10% lyophilized resin of natural Chios mastic.
• Mastiha var. Chia Powder (Μαστίχα Χίου Σκόνη) Chios Mastic powder product in 15 sachets packaging for various therapeutic applications including gastrointestinal indications.
• Glucofree® & Glucoplus® Metformin hydrochloride film-coated tablets for Type 2 diabetes treatment; Glucofree (850mg) and Glucoplus (1000mg) in boxes of 60 film-coated tablets.
• MAG-IASIS® Magnesium combination product with 1193.57mg Magnesium citrate and 667.56mg Magnesium aspartate (equivalent to 243mg Magnesium) for magnesium deficiency, in 40 effervescent tablets.
• Modiwart® Imiquimod 12.5mg/sachet immunomodulator for external genital warts, superficial basal cell carcinomas, and actinic keratoses.
• Combi® Combination of fluprednidene (1mg) and miconazole (20mg) in 50g cream for inflammatory dermatomycoses.
• Etrozac® Etoricoxib selective COX-2 inhibitor for relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and inflammation symptoms.
• Licepler® Eplerenone product available in 30 film-coated tablets in 25mg and 50mg strengths for cardiovascular indications.
• COVED® Alendronic acid 70mg with cholecalciferol 5,600IU for postmenopausal osteoporosis treatment and vitamin D deficiency.
• Sensibio® Combination of Fusidic Acid (2%) and Betamethasone Valerate (0.1%) in cream form for dermatological conditions, available in 15g and 30g packaging.
• Flusterix® Antibiotic cream for external use, available in 15g and 30g packaging.
• Zylapour® Allopurinol product (xanthine oxidase inhibitor) for gout treatment, available in 100mg x 30 tabs, 100mg x 100 tabs, and 300mg x 30 packages.

Quantifiable outcome

• EMA 2015 recognition of Chios Mastic as Herbal Medicine for functional dyspepsia and skin wound healing
• +2 more outcomes

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core.

• Union of Chios Mastic Producers (E.M.X. / E.M.Χ.)coreStrategic or Co-development Partner · 1 November 2021The Union of Chios Mastic Producers collaborates with IASIS PHARMA on the HYPER-MASTIC research project to develop innovative antihypertensive phytotherapeutic products based on Chios Mastic. The union represents producers of the Protected Designation of Origin Chios Mastic ingredient.
• Harokopio University of Athens - Department of Nutrition and DieteticscoreStrategic or Co-development Partner · 1 November 2021Academic research partner in the HYPER-MASTIC project, contributing scientific expertise on bioactive natural products and their effects on cardiovascular health. The university brings pharmacological research capabilities to the collaboration.
• National and Kapodistrian University of Athens (NKUA) - Faculty of Pharmacy, Department of PharmacognosycoreStrategic or Co-development Partner · 1 November 2021Key academic partner in Chios Mastic research. The Department of Pharmacognosy authored the most updated pharmacological review of Chios Mastic's properties and coordinates the HYPER-MASTIC project. Also involved in the Competence Center for Natural Products.
• Therapeutic Clinic of the Medical School (Hellenic School)coreStrategic or Co-development Partner · 1 November 2021Clinical research partner in the HYPER-MASTIC project, contributing medical and clinical expertise for the development and testing of Chios Mastic-based antihypertensive products.
• Competence Center for Natural Products (ΚΙΦΠ)coreStrategic or Co-development Partner · 1 September 2021IASIS PHARMA co-founded the Competence Center for Natural Products (ΚΙΦΠ), a Cooperative Innovation Formation with 15 partners from academic and business sectors. Coordinated by the Laboratory of Exploitation of Bioactive Natural Products, Faculty of Pharmacy (NKUA). Focuses on research and innovation in Greek natural product-based pharmaceuticals.
• IMA Group (Italy)coreTechnology or Integration · 1 September 2021IMA Group, based in Italy, is the world leader in automated pharmaceutical manufacturing equipment design and construction. IASIS PHARMA selected IMA technology for its effervescent tablet production line, achieving top-quality production with extremely high production rates at its Koropi facility.
• Chios Mastic Research CentercoreStrategic or Co-development Partner · 1 July 2017IASIS PHARMA maintains active participation in the Chios Mastic Research Center, established in Kallimachia, Chios in summer 2017. The center conducts research on applications of Chios Mastic and collaborates on product development.
• Pharma QcoreChannel Partner/ Reseller/ DistributorPharma Q is the sales and distribution partner for IASIS PHARMA products in Greece. Dr. Christos Zavos, Gastroenterologist-Hepatologist, presented the Mastiha powder product to Pharma Q sales partners at the new IASIS PHARMA facilities in Koropi.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Vianex: Established Greek pharmaceutical manufacturer with branded-generic portfolio across multiple therapeutic areas; comparable in domestic Greek market position and portfolio breadth.
• Stada Arzneimittel: European specialty generics and consumer health company with branded-generic portfolio across cardiovascular, dermatology, and CNS — comparable business model of specialty generics with proprietary branded positioning in European markets.
• Help Pharmaceuticals: Greek branded-generic manufacturer with portfolio overlap in cardiovascular, CNS, and dermatology, and a similar pattern of proprietary FDC launches in the domestic Greek market.
• Elpen Pharmaceutical: Greek pharmaceutical manufacturer with overlapping branded-generic and specialty pharma portfolio across cardiovascular, respiratory, and CNS categories, operating its own GMP manufacturing in Greece — the closest scale and model match to IASIS.
• Rafarm: Greek specialty pharmaceutical company with branded generics, ophthalmics, and proprietary formulations; comparable in mid-sized Greek specialty pharma profile and export orientation.
• Specifar Pharmaceuticals (Aenova Group): Greek-origin generic pharmaceutical manufacturer now part of Aenova; directly comparable as a Greek-based generic manufacturer with international distribution into regulated European markets.
• Pharmathen: Greek specialty generics developer with broad therapeutic coverage and strong international footprint; comparable business model as a Greek-origin branded-generic producer with proprietary formulation capabilities.
• Demo Pharmaceutical: One of the largest Greek pharmaceutical manufacturers with broad branded-generic portfolio across cardiovascular, CNS, anti-infectives, and dermatology — comparable in therapeutic breadth and Greek market focus.

Broad incumbents

• Sandoz (Novartis): Global generics and biosimilars division with deep European presence and overlapping portfolio in cardiovascular, dermatology, and CNS categories; relevant as the broad incumbent defining the competitive context for branded-generic strategies.
• Teva Pharmaceutical: Global generics leader offering overlapping therapeutic categories including isotretinoin, metformin, and cardiovascular products; relevant as a broad incumbent setting pricing and competition dynamics in categories where IASIS operates.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/iasispharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iasis Pharma